Table 1.
Patients’ and azacitidine treatment characteristics.
| Characteristics | n (%) |
|---|---|
| Sex | |
| Male | 177 (57.6%) |
| Female | 130 (42.4%) |
| Age, median (range); years | 71 (18–95) |
| WHO 2016 diagnosis | |
| AML | 116 (37.8%) |
| MDS | 169 (55.0%) |
| CMML | 22 (7.1%) |
| IPSS | |
| Low | 1 (0.3%) |
| Int 1 | 16 (5.2%) |
| Int 2 | 102 (33.2%) |
| High | 89 (28.9%) |
| NA | 99 (33.2%) |
| IPSS-R | |
| Very Low | 0 (0.0%) |
| Low | 2 (0.6%) |
| Intermediate | 21 (6.8%) |
| High | 75 (24.4%) |
| Very High | 103 (33.5%) |
| NA | 106 (34.5%) |
| ECOG Performance Status | |
| 0–1 | 213 (69.3%) |
| 2–4 | 94 (30.7%) |
| MDS Comorbidity Index | |
| 0-1 2-3 |
231 (75.4%) 76 (24.6%) |
| BMI | |
| <25 kg/m2
≥ 25 kg/m2 No data |
107 (34.8%) 161 (52.4%) 39 (12.8%) |
| Transfusion dependency | |
| RBC TD | 168 (54.7%) |
| PLT TD | 71 (23.1%) |
| Comorbidities | |
| DM | 67 (21.8%) |
| COPD | 22 (7.1%)) |
| Cardiac failure (NYHA III/IV) |
40 (13.2%) |
| Second malignancy | 68 (22.1%) |
| Corticosteroid treatment | 18 (20.4) |
| Autoimmune disease | 41 (13.3%) |
| Tobacco smokers | 86 (28.0%) |
| MRB colonization | 50 (16.2%) |
| Antimicrobial Prophylaxis | |
| Antibacterial | 205 (66.0%) |
| Antifungal Antiviral |
90 (29.3%) 79 (25.7%) |
| 5-AZA administration | |
| Inpatient | 243 (79.2%) |
| Outpatient | 64 (20.8%) |
WHO, World Health Organization; AML, acute myeloid leukemia; MDS, myelodysplastic syndromes; CMML, chronic myelomonocytic leukemia; ECOG, Eastern Cooperative Oncology Group; IPSS, international prognostic scoring system; IPSS-R, revised international prognostic scoring system; MDS, myelodysplastic syndrome; RBC TD, Red Blood Cell Transfusion Dependence; PLT TD, Platelet Transfusion Dependence; NYHA, New York Heart Association; DM, Diabetes mellitus; COPD, Chronic obstructive pulmonary disease; MRB, multidrug-resistant bacteria; 5-AZA, azacitidine.